RESUMEN
The Yellow River Delta possesses lots of characteristic medicinal plants due to its high salinity and high alkaline environment and Limonium sinense is an iconic plant. However, there are very few studies on L. sinense and its chemical constituents have not been investigated in recent ten years. In the present study, the chemical constituents and bioactivities of L. sinense were fully studied for the first time. UPLC-MS/MS method combined with database comparison identified 109 compounds mainly including flavonoids, alkaloids and polyphenols. In addition, the potential bioactivities of L. sinense were considerated as anti-inflammatory, anti-oxidative, anti-tumor, hepatoprotective and hpyerglycemic activities based on these identified compounds and their related literature. Furthermore, four derivatives of 12-oxo-phytodienoic acid and butenolide including two new ones (1 and 2) were isolated from the whole plants of L. sinense. Their structures, including the absolute configurations, were determined by the analysis of comprehensive spectroscopic data. All isolates were evaluated for their anti-inflammatory activity. Compound 1 exhibited moderate anti-inflammatory activity with IC50 value of 37.5 ± 1.2 µM on NO production level.
RESUMEN
OBJECTIVE: To identify whether Banxia Xiexin Decoction (BXD) alleviates cerebral glucose metabolism disorder by intestinal microbiota regulation in APP/PS1 mice. METHODS: Forty-five 3-month-old male APP/PS1 mice were divided into 3 groups using a random number table (n=15 per group), including a model group (MG), a liraglutide group (LG) and a BXD group (BG). Fifteen 3-month-old male C57BL/6J wild-type mice were used as the control group (CG). Mice in the BG were administered BXD granules by gavage at a dose of 6 g/(kgâ¢d) for 3 months, while mice in the LG were injected intraperitoneally once daily with Liraglutide Injection (25 nmol/kg) for 3 months. Firstly, liquid chromatography with tandem-mass spectrometry was used to analyze the active components of BXD granules and the medicated serum of BXD. Then, the cognitive deficits, Aß pathological change and synaptic plasticity markers, including synaptophysin (SYP) and postsynaptic density protein 95 (PSD95), were measured in APP/PS1 mice. Brain glucose uptake was detected by micropositron emission tomography. Intestinal microbial constituents were detected by 16S rRNA sequencing. The levels of intestinal glucagon-like peptide 1 (GLP-1) and cerebral GLP-1 receptor (GLP-1R), as well as the phosphoinositide-3-kinase/protein kinase B/glycogen synthase kinase-3ß (PI3K/Akt/GSK3ß) insulin signaling pathway were determined by immunohistochemical (IHC) staining and Western blot analysis, respectively. RESULTS: BXD ameliorated cognitive deficits and Aß pathological features (P<0.01). The expressions of SYP and PSD95 in the BG were higher than those in the MG (P<0.01). Brain glucose uptake in the BG was higher than that in the MG (P<0.01). The intestinal microbial composition in the BG was partially reversed. The levels of intestinal GLP-1 in the BG were higher than those in the MG (P<0.01). Compared with the MG, the expression levels of hippocampal GLP-1R, Akt, PI3K and p-PI3K in the BG were significantly increased (P<0.01), while the levels of GSK3ß were reduced (P<0.01). CONCLUSION: BXD exhibited protective effects against Alzheimer's disease by regulating the gut microbiota/GLP-1/GLP-1R, enhancing PI3K/Akt/GSK3ß insulin signaling pathway, and improving brain glucose metabolism.
RESUMEN
OBJECTIVE: To determine the effects of different formulations of Banxia Xiexin Decoction ( , BXD) on the pharmacokinetics of baicalin (BAL) in mice. METHODS: Pungent, bitter, and sweet components of BXD (totaling 7 Chinese herbs) were formulated into the following groups: K (bitter herbs), XK (pungent and bitter herbs), KG (bitter and sweet herbs), and BXD (all 7 herbs) groups. These different formulations were administered intragastrically in mice, and blood was collected via the tail vein for continuous monitoring. BAL, which is a main active constituent in Scutellaria baicalensis Georgi., was detected in this study. Indirect competitive enzyme-linked immunosorbent assays (icELISAs) based on anti-BAL-monoclonal antibodies were employed to determine BAL concentrations in each group. RESULTS: The concentrations of BAL in blood samples from mice in the K and XK groups were lower than those in other groups. In all groups, BAL concentrations peaked at around 1-1.5 h and again at 5-7 h. There were no significant differences in the timing of peak BAL concentrations between groups. However, the peak concentrations and area under curve (AUC)0-36 h in the KG and BXD groups were almost 3 times of those in the K and XK groups. CONCLUSIONS: Differing compatibilities of BXD caused dissimilar pharmacokinetics of BAL. Moreover, we demonstrated a method for the continuous detection of blood concentrations of Chinese medicines in mice, and icELISA may be a feasible technique for the study of pharmcokinetic mechanisms of Chinese medicine.